<td class= Dadun
   (New user)
Help  | Contact  |  Castellano English  

Dadun > Depósito Académico > Facultad de Farmacia > Departamento de Farmacia y Tecnología Farmacéutica > DA - Farmacia - Tecnología Farmacéutica - Artículos de revista >

Effective GDNF brain delivery using microspheres-A promising strategy for Parkinson’s disease
Authors: Garbayo, E. (Elisa)
Monter-Menei, C.N. (C.N.)
Ansorena, E. (Eduardo)
Lanciego, J.L. (José Luis)
Aymerich, M.S. (María S.)
Blanco-Prieto, M.J. (María José)
Keywords: GDNF
PLGA microparticles
Serum IgG antibodies against GDNF
Parkinson´s disease
Issue Date: 2009
Publisher: Elsevier
Publisher version:
ISSN: 0168-3659
Citation: Garbayo E, Montero-Menei CN, Ansorena E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ. Effective GDNF brain delivery using microspheres--a promising strategy for Parkinson's disease. J Control Release 2009 Apr 17;135(2):119-126.
Glial cell line-derived neurotrophic factor (GDNF) has shown promise in the treatment of neurodegenerative disorders of basal ganglia origin such us Parkinson's disease (PD). In this study, we investigated the neurorestorative effect of controlled GDNF delivery using biodegradable microspheres in an animal model with partial dopaminergic lesion. Microspheres were loaded with N-glycosylated recombinant GDNF and prepared using the Total Recirculation One-Machine System (TROMS). GDNF-loaded microparticles were unilaterally injected into the rat striatum by stereotaxic surgery two weeks after a unilateral partial 6-OHDA nigrostriatal lesion. Animals were tested for amphetamine-induced rotational asymmetry at different times and were sacrificed two months after microsphere implantation for immunohistochemical analysis. The putative presence of serum IgG antibodies against rat glycosylated GDNF was analyzed for addressing safety issues. The results demonstrated that GDNF-loaded microspheres, improved the rotational behavior induced by amphetamine of the GDNF-treated animals together with an increase in the density of TH positive fibers at the striatal level. The developed GDNF-loaded microparticles proved to be suitable to release biologically active GDNF over up to 5 weeks in vivo. Furthermore, none of the animals developed antibodies against GDNF demonstrating the safety of glycosylated GDNF use.
Permanent link:
Appears in Collections:DA - Ciencias - HAP - Artículos de revista
DA - Farmacia - Tecnología Farmacéutica - Artículos de revista
DA - CIMA - Neurociencias - Neuroanatomía ganglios basales - Artículos de Revista

Files in This Item:
File:  Garbayo et al-manuscript-Revised-JCR-08-00852R1.pdf
Size:  630,29 kB
Format:  Adobe PDF
 View / Open 

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.